© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Viridian Therapeutics, Inc. (VRDN) shows an Average True Range (ATR) of 1.25 and an Enterprise Value of 736.08M. Its average trading volume over the past 3 months is 1.5M, indicating liquidity. These fundamental metrics provide insight into VRDN's underlying financial health and market activity.
Viridian Therapeutics, Inc. (VRDN) technical indicators as of December 23, 2025: the SMA 20 is 1.48%, SMA 50 at 16.36%, and SMA 200 at 70.65%. The RSI 14 value is 62.49, suggesting its current momentum. These technical analysis signals help assess VRDN's price trends and potential future movements.
Viridian Therapeutics, Inc. (VRDN) stock performance overview as of December 23, 2025: The 52-week high is $34.04 (currently -4.61% below), and the 52-week low is $9.9 (currently 227.98% above). Over the past year, VRDN's performance is 50.74%, compared to the S&P 500's 10.56% change.
According to market data, Viridian Therapeutics, Inc. (VRDN) stock's recent performance metrics show that over the last month, VRDN is 13.21%, with a Year-to-Date (YTD) performance of 69.38%. Over the past year, the stock has seen a 50.74% change. These figures summarize VRDN's price movements across various periods, reflecting its historical returns.
According to current financial data, VRDN stock's P/E (TTM) ratio is -7.61, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for VRDN, including P/S (8539.58), P/B (5.08), and P/FCF (-8.41), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.